Chenglong Han

4.7k citations

118 papers · 3.5k indexed · 2 hit papers · h-index 32

Impact in

Rheumatology top 0.2%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Lupus Erythematosus Research
Hematology top 1%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 53
- Rheumatoid Arthritis Research and Therapies 40
- Spondyloarthritis Studies and Treatments 25
Dermatology 21
- Dermatology and Skin Diseases 18

Co-authors: Mohan Bala Kathy Fraeman L. Clark Paramore Don Robinson Josef S Smolen Ravinder N. Maini Brad Schenkel Désirée van der Heijde
Journals: Annals of the Rheumatic Diseases (19 papers)Value in Health (9 papers)Gastroenterology (8 papers)The American Journal of Gastroenterology (8 papers)Journal of Dermatological Treatment (5 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Chenglong Han

106 papers receiving 3.3k citations

Hit Papers

align trajectories log scale

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study 2022 · 132 citations

Peers

Countries citing papers authored by Chenglong Han

Since Specialization

Citations

This map shows the geographic impact of Chenglong Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenglong Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenglong Han more than expected).

Fields of papers citing papers by Chenglong Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenglong Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenglong Han. The network helps show where Chenglong Han may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Chenglong Han, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chenglong Han Line = papers co-authored together Chenglong Han links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	— Invited Review — Challenges and constraints to the sustainability of poultry farming in China Animal Bioscience ·Fei Zhang, Z. J. Chen, Judith Escalante-Calcina, Chenglong Han, 김용화КимЙонгфа, Zhouzheng Ren, Xiaojun Yang	2025	2
2	Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis Dermatology and Therapy ·April W. Armstrong, Peter Foley, Yan Liu, Mitchell D. Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim Papp, Chenglong Han	2024	5
3	Prognosis associated with several different post-treatment reactions after hemoporfin mediated photodynamic therapy Photodiagnosis and Photodynamic Therapy ·Bisig, Mariana Côrtes de Freitas, Chenglong Han, Xian Jiang	2024	1
4	Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2 Journal of Investigative Dermatology ·Andrew Blauvelt, Kenneth B. Gordon, Richard G. Langley, Patrick Branigan, Yanqing Chen, Megan Miller, Chenglong Han, S. Fakharzadeh, Ernesto J. Muñoz‐Elías, April W. Armstrong	2024	0
5	Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis Rheumatology and Therapy ·Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven L. Peterson, Gracy C G Marcello, Oluwakayode Adejoro, Alexa P. Kollmeier, Natalie J. Shiff, Chenglong Han, M. Shawi, William Tillett, Philip J. Mease	2024	0
6	43927 The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials Journal of the American Academy of Dermatology ·April W. Armstrong, L. Puig, Kim Papp, Marcie Strauss, Ya‐Wen Yang, I V Suzdaltsev, Mitchell D. Miller, Jenny E. Murase, Pablo Fernández‐Peñas, Chenglong Han	2023	1
7	Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease Journal of Patient-Reported Outcomes ·Brian G. Feagan, William J. Sandborn, Bruce E. Sands, Yan Liu, Marion Vetter, Susan D. Mathias, Kuan‐Hsiang Gary Huang, Jewel Johanns, Matthew Germinaro, Chenglong Han	2023	6
8	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1 Journal of Dermatological Treatment ·C.E.M. Griffiths, Kim Papp, Michael Song, Megan Miller, Yin You, Yaung‐Kaung Shen, Chenglong Han, Andrew Blauvelt	2020	32
9	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial Value in Health ·John D. Reveille, Atul Deodhar, Akgun Ince, Eric K. H. Chan, Steven L. Peterson, Nan Li, Elizabeth C. Hsia, Lilianne Kim, Kim Hung Lo, Stephen Xu, Diane D. Harrison, Chenglong Han	2020	6
10	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial Value in Health ·M. Elaine Husni, Arthur Kavanaugh, Eric K. H. Chan, Steven L. Peterson, Nan Li, Elizabeth C. Hsia, Lilianne Kim, Kim Hung Lo, Diane D. Harrison, Chenglong Han	2020	4
11	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study American Journal of Clinical Dermatology ·Kristian Reich, April W. Armstrong, Peter Foley, Michael Song, Megan Miller, Yaung‐Kaung Shen, Yin You, Chenglong Han, Kenneth B. Gordon	2020	27
12	COGNITIVE DEBRIEFING OF THE SF-36V2 WITH MODERATE-TO-SEVERE CROHN’S DISEASE PATIENTS Value in Health ·Marie White, Aaron Yarlas, M. Ingham, Chenglong Han	2016	2
13	Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial The Journal of Rheumatology ·Edward Keystone, Mark C. Genovese, Stephen Hall, Sang‐Cheol Bae, Chenglong Han, Timothy Gathany, Stephen Xu, Yiying Zhou, Jocelyn H. Leu, Elizabeth C. Hsia	2015	35
14	Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study Annals of the Rheumatic Diseases ·Atul Deodhar, Jürgen Braun, Robert D. Inman, Désirée van der Heijde, Yiying Zhou, Stephen Xu, Chenglong Han, Benjamin Hsu	2014	101
15	Development Of A Patient-Reported Outcomes Measure For Psoriasis: The Psoriasis Symptoms, Signs, And Impact Questionnaire Value in Health ·Steven R. Feldman, Susan D. Mathias, Brad Schenkel, Hilary H. Colwell, Rahul Ganguly, Yasmine Wasfi, B. Randazzo, Chenglong Han	2014	1
16	Achieving Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein Major Improvement and Inactive Disease in Patients with Ankylosing Spondylitis after Treatment with Golimumab is Associated with Normalized Health Related Quality of Life: 2-Year Results from GO-RAISE Lara D. Veeken ·Robert D. Inman, Atul Deodhar, Jürgen Braun, M. Mack, Sia Kolkovska, 张景忠 ZHANG Jing-zhong, Chenglong Han, Désirée van der Heijde	2013	1
17	Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials Value in Health ·Ingrid Strusberg, Bernardo A. Pons‐Estel, Pedro C. Miranda, Mark C. Genovese, Roy Fleischmann, Andrea Puig, Chenglong Han, Elizabeth C. Hsia	2013	1
18	PREDICTORS OF RADIOGRAPHIC PROGRESSION IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON ONE-YEAR RADIOGRAPHIC DATA FROM THE GO-BEFORE GOLIMUMAB CLINICAL TRIAL Data Archiving and Networked Services (DANS) ·Paul Emery, (unknown), Chenglong Han, Fāi sapphayākǭn thammachāt læ sing wǣt lǭm, Philip G. Conaghan, W. Xu, E. C. Hsia	2012	1
19	Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab Arthritis Care & Research ·Jürgen Braun, Désirée van der Heijde, Mittie K. Doyle, Chenglong Han, Atul Deodhar, Robert D. Inman, Kurt de Vlam, Gerd R Burmester, Filip Van den Bosch, Stephen Xu, Sudha Visvanathan, Mahboob U. Rahman	2009	27
20	Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial Arthritis & Rheumatism ·Josef S Smolen, Désirée van der Heijde, E. William St. Clair, Paul Emery, Joan M. Bathon, Edward Keystone, Ravinder N. Maini, Joachim R. Kalden, Michael Schiff, Daniel Baker, Chenglong Han, John Han, Mohan Bala, (unknown)	2006	342

About Chenglong Han

Chenglong Han is a scholar working on Rheumatology, Dermatology, Hematology, Immunology and Genetics, having authored 118 papers that have together received 3.5k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (40 papers), Psoriasis: Treatment and Pathogenesis (39 papers), Spondyloarthritis Studies and Treatments (25 papers), Autoimmune and Inflammatory Disorders Research (24 papers), Inflammatory Bowel Disease (24 papers), Microscopic Colitis (20 papers), Dermatology and Skin Diseases (18 papers) and Chronic Lymphocytic Leukemia Research (16 papers). The work is most often cited by research in Rheumatology (2.0k citations), Hematology (892 citations), Immunology (1.5k citations), Dermatology (563 citations) and Biological Psychiatry (143 citations). Chenglong Han has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Mohan Bala, Kathy Fraeman, L. Clark Paramore, Don Robinson, Josef S Smolen, Ravinder N. Maini, Brad Schenkel, Désirée van der Heijde, John Han and Joan M. Bathon. Their work appears in journals such as Annals of the Rheumatic Diseases, Value in Health, Gastroenterology, The American Journal of Gastroenterology and Journal of Dermatological Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact